ID: ALA4741603

Max Phase: Preclinical

Molecular Formula: C14H24ClNO

Molecular Weight: 221.34

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  Cc1cccc(C)c1OCC(N)C(C)(C)C.Cl

Standard InChI:  InChI=1S/C14H23NO.ClH/c1-10-7-6-8-11(2)13(10)16-9-12(15)14(3,4)5;/h6-8,12H,9,15H2,1-5H3;1H

Standard InChI Key:  IRJJJVSXFHGISN-UHFFFAOYSA-N

Associated Targets(Human)

HepG2 196354 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Left atrium 264 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Right atrium 265 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Aorta 327 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Ileum 856 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 221.34Molecular Weight (Monoisotopic): 221.1780AlogP: 3.06#Rotatable Bonds: 3
Polar Surface Area: 35.25Molecular Species: BASEHBA: 2HBD: 1
#RO5 Violations: 0HBA (Lipinski): 2HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 9.34CX LogP: 3.73CX LogD: 1.82
Aromatic Rings: 1Heavy Atoms: 16QED Weighted: 0.85Np Likeness Score: -0.30

References

1. Roselli M,Carocci A,Budriesi R,Micucci M,Toma M,Di Cesare Mannelli L,Lovece A,Catalano A,Cavalluzzi MM,Bruno C,De Palma A,Contino M,Perrone MG,Colabufo NA,Chiarini A,Franchini C,Ghelardini C,Habtemariam S,Lentini G.  (2016)  Synthesis, antiarrhythmic activity, and toxicological evaluation of mexiletine analogues.,  121  [PMID:27267000] [10.1016/j.ejmech.2016.05.046]
2. Cashman JR, Ryan D, McKeithan WL, Okolotowicz K, Gomez-Galeno J, Johnson M, Sampson KJ, Kass RS, Pezhouman A, Karagueuzian HS, Mercola M..  (2021)  Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.,  64  (9.0): [PMID:33942619] [10.1021/acs.jmedchem.0c01545]

Source